Alan Mateo Buys 40,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo bought 40,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were bought at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the purchase, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

10x Genomics Price Performance

10x Genomics stock traded down $0.18 during midday trading on Tuesday, reaching $11.11. The company’s stock had a trading volume of 3,650,293 shares, compared to its average volume of 2,617,122. The stock has a market capitalization of $1.36 billion, a P/E ratio of -7.31 and a beta of 1.85. The stock’s 50-day simple moving average is $14.23 and its 200-day simple moving average is $17.02. 10x Genomics, Inc. has a 52-week low of $10.63 and a 52-week high of $48.42.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities research analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TXG shares. Morgan Stanley reduced their price target on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Canaccord Genuity Group decreased their price target on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. UBS Group dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. reduced their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Finally, Citigroup decreased their price target on 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $20.57.

Institutional Investors Weigh In On 10x Genomics

A number of hedge funds have recently modified their holdings of TXG. KBC Group NV grew its position in 10x Genomics by 38.8% in the third quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after acquiring an additional 902 shares during the period. Atria Wealth Solutions Inc. boosted its stake in shares of 10x Genomics by 9.6% in the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock valued at $155,000 after purchasing an additional 943 shares during the period. First Horizon Advisors Inc. raised its stake in shares of 10x Genomics by 53.3% in the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock valued at $66,000 after acquiring an additional 1,012 shares in the last quarter. Blue Trust Inc. grew its position in shares of 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after buying an additional 1,025 shares in the last quarter. Finally, Sound Income Strategies LLC grew its holdings in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.